Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Fremont, California 94555


Purpose:

To determine if ABX-IL8 will improve shortness of breath.


Study summary:

Chronic Obstructive Pulmonary Disease (COPD) is defined as a disease state characterized by the presence of airflow obstruction due to chronic bronchitis or emphysema. The airflow obstruction is generally progressive, may be accompanied by airway hyper-reactivity, and may be partially reversible. Inflammation in the lungs is triggered by exposure to inhaled toxic substances that can lead to tissue damage, mucous secretion, airways narrowing and tissue destruction. Interleukin-8 (IL-8) plays a major role in elevating sputum in patients with COPD and may contribute to tissue destruction. Therefore, the highly specific antibody to IL-8 (such as ABX-IL8) may help to reduce mucous production and tissue destruction.


Criteria:

Inclusion Criteria: - > 50 years old - > 20 pack-year of smoking - Diagnosed with COPD and chronic bronchitis Exclusion Criteria: - Patients with bronchiectasis, cystic fibrosis, tuberculosis, asthma, alpha-1 antitrypsin deficiency, CHF - Require oxygen therapy - Uncontrolled hypertension - HIV or Hepatitis - Recent history of COPD exacerbation - Patients with cancer - Recent history of infection


NCT ID:

NCT00035828


Primary Contact:

N/A


Backup Contact:

N/A


Location Contact:

Fremont, California 94555
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 10, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.